噻托溴铵联合福莫特罗与沙美特罗替卡松治疗稳定期慢性阻塞性肺疾病的疗效观察

Observation on the clinical efficacy of tiotropium combined with formoterol and salmeterol in the treatment of patients with chronic obstructive pulmonary disease

目的探讨噻托溴铵联合福莫特罗治疗稳定期慢性阻塞性肺疾病患者的临床疗效。方法选取我院诊治的130例中重度慢性阻塞性肺疾病患者。采用数字表法随机分为噻托溴铵联合福莫特罗组(A组)和沙美特罗替卡松组(B组),每组各65例,治疗12周后,比较2组的肺功能(第1秒用力肺活量、用力肺活量)和CAT评分。结果治疗12周后,2组患者FEV1、FVC及CAT评分较治疗前均明显增高,治疗前后比较差异均有统计学意义(P<0.05)。治疗后,A组患者FEV1、FVC高于B组,2组比较差异有统计学意义(P<0.05)。CAT评分2组差异无统计学意义(P>0.05)。结论治疗12周后,噻托溴铵联合福莫特罗组对中重度COPD患者的肺功能的提高明显优于沙美特罗替卡松。

Objective To investigate the clinical efficacy of tiotropium combined with formoterol and salmeterol/fluticasone in the treatment of patients with stable chronic obstructive pulmonary disease （COPD）. Methods One hundred and thirty patients with moderate-to-severe COPD admitted into the hospital for treatment were enrolled for the study, and were randomized into the tiotropium plus formoterol group （or group A） and the salmeterol/fluticasone group （or group B）. Following treatment for 12 weeks, scores of pul-monary functions （ FEV1 禾口 FV C） ,as well as scores of CAT were compared between the 2 groups. Results Twelve weeks after treat-ment ,the scores of FEV1, FVC and COPD of the 2 groups were all obviously increased, as compared with those before treatment, and statistical significance could be noticed, when comparisons were made between pre and post treatment （P 〈0. 0 5 ） . After treatment, the scores of FEV1 and FVC of group A were all higher than those of group B, and statistical significance could be seen, when comparisons were made between them （P 〈0. 0 5 ） . However, there was no statistical significance in the CAT scores, when comparisons were made between the 2 groups （P 〉0. 0 5 ） . Conclusion After 12 weeks of treatment, tiotropium plus formoterol therapy was obviously superior to salmeterol/fluticasone therapy in the improvement of the pulmonary functions （FEV1 and FVC） in the patients with moderate-to-se- vere COPD.